Disputes And Challenges Of Immune Checkpoint Inhibitors In Gastrointestinal Cancers
Download Disputes And Challenges Of Immune Checkpoint Inhibitors In Gastrointestinal Cancers full books in PDF, epub, and Kindle. Read online free Disputes And Challenges Of Immune Checkpoint Inhibitors In Gastrointestinal Cancers ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Hongwei Yao |
| Publisher | : Frontiers Media SA |
| Total Pages | : 134 |
| Release | : 2024-05-15 |
| Genre | : Science |
| ISBN | : 2832549101 |
Recently, immune checkpoint inhibitors (ICIs) have received a lot of attention to treat gastrointestinal cancers. Compared with traditional treatments, immunotherapy can kill cancer cells by activating the antitumor immunity, the specific recognition of cancer antigens preventing normal cells from being attacked. However, the application of ICIs is accompanied by a series of specific toxic reactions caused by the functional stimulation of the immune system, which are called immune-related adverse events (irAEs). Early identification and timely intervention to handle irAEs are usually required to maximize the therapeutic effect of ICIs. In addition, related surgical complications after neoadjuvant immunotherapy is increasingly reported. Thus, although immunotherapy has shown obvious advantages in the clinical treatment of gastrointestinal cancers, the safety and potential risks of such treatment have to be considered. Many clinical studies have shown that cancer patients receiving neoadjuvant immunotherapy experience different degrees of immune-inflammatory reaction, immune disorders, immune-related pneumonia, and other adverse events. In addition, some patients suffering from irAEs during the treatment have to face a delayed operation or even lose the opportunity to be operated. Finally, because the clinical imaging manifestations of immunotherapy are complex and diverse, the imaging evaluation criteria have so far not been standardized. The aim of this Research Topic is to report disputes and challenges of immune checkpoint inhibitors in gastrointestinal cancers. We welcome original research articles, Review articles, Mini Reviews, and Case reports. Preferred topics include but are not limited to the following: • Timely discovery of immune-related adverse events during immunotherapy • Identification and differentiation between immune-related adverse events and adverse drug events • Treatment and drug withdrawal timing upon immune-related adverse events • Management of related surgical complications after neoadjuvant immunotherapy • Imaging evaluation criteria or methods of immunotherapy efficacy
| Author | : Marc S. Ernstoff, MD |
| Publisher | : Springer Publishing Company |
| Total Pages | : 275 |
| Release | : 2019-03-15 |
| Genre | : Medical |
| ISBN | : 0826172156 |
The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer
| Author | : Fumito Ito |
| Publisher | : Elsevier Health Sciences |
| Total Pages | : 271 |
| Release | : 2018-09-03 |
| Genre | : Medical |
| ISBN | : 0323549500 |
Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. - Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. - Helps you translate current research and literature into practical information for daily practice. - Presents information logically organized by disease site. - Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. - Consolidates today's available information on this timely topic into one convenient resource.
| Author | : |
| Publisher | : |
| Total Pages | : |
| Release | : |
| Genre | : |
| ISBN | : |
| Author | : Tim F. Greten |
| Publisher | : Springer |
| Total Pages | : 0 |
| Release | : 2018-08-22 |
| Genre | : Medical |
| ISBN | : 9783319879116 |
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
| Author | : Peter L. Stern |
| Publisher | : Cambridge University Press |
| Total Pages | : 304 |
| Release | : 2000-08-17 |
| Genre | : Medical |
| ISBN | : 9780521622639 |
Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments.
| Author | : S. Peters |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 126 |
| Release | : 2014-02-19 |
| Genre | : Medical |
| ISBN | : 3318025429 |
The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 135 |
| Release | : 2016-12-10 |
| Genre | : Medical |
| ISBN | : 030944232X |
Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.
| Author | : Luciano Adorini |
| Publisher | : S. Karger AG (Switzerland) |
| Total Pages | : 184 |
| Release | : 1995 |
| Genre | : Medical |
| ISBN | : |
| Author | : Suzanne Russo |
| Publisher | : Springer |
| Total Pages | : 365 |
| Release | : 2017-12-30 |
| Genre | : Medical |
| ISBN | : 3319649000 |
This book is a practical guide on how best to incorporate advanced radiation therapy techniques into the multimodality treatment of a wide range of gastrointestinal tumors, including esophageal cancer, gastric cancer, hepatobiliary malignancies (primary and metastatic liver tumors, intrahepatic, perihilar, and extrahepatic cholangiocarcinomas, and gallbladder cancer), pancreatic cancer, colorectal cancer, and carcinoma of the anal canal. Practical considerations when treating patients with external beam radiation therapy, intensity-modulated radiation therapy, particle therapy, and stereotactic body radiation therapy are clearly explained. Detailed attention is devoted to the safety and efficacy of radiotherapy in combination with current and emerging systemic therapies (chemotherapy, immunotherapy, and biologic agents), surgery, and ablative therapy, and the advantages and disadvantages of alternative treatment approaches for different tumor types are carefully evaluated. The book will benefit radiation oncologists, medical and surgical oncologists, medical physicists, medical dosimetrists, and other oncology professionals.
